Sorry, you need to enable JavaScript to visit this website.

Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R ± T790M)

Phase 1/2 Open-Label Study of PF-06747775 (Epidermal Growth Factor Receptor T790M Inhibitor) in Patients With Advanced Epidermal Growth Factor Receptor Mutant (Del 19 or L858R ± T790M) Non-Small Cell Lung Cancer

Category & Conditions: Cancer
Medicine: PF-06747775
ClinicalTrials.gov Identifier (NCT): NCT02349633
Protocol ID: B7971001
    Share
PrintDownload
Open Plain Language Summary Result: Click here